Department of Radiology, Jinling Hospital, Affiliated Nanjing Medical University, Nanjing, China; Department of Radiology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
School of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, China.
J Adv Res. 2024 Nov;65:257-271. doi: 10.1016/j.jare.2023.12.002. Epub 2023 Dec 10.
Combination immunotherapy holds promise for improving survival in responsive glioblastoma (GBM) patients. Programmed death-ligand 1 (PD-L1) expression in immune microenvironment (IME) is the most important predictive biomarker for immunotherapy. Due to the heterogeneous distribution of PD-L1, post-operative histopathology fails to accurately capture its expression in residual tumors, making intra-operative diagnosis crucial for GBM treatment strategies. However, the current methods for evaluating the expression of PD-L1 are still time-consuming.
To overcome the PD-L1 heterogeneity and enable rapid, accurate, and label-free imaging of PD-L1 expression level in GBM IME at the tissue level.
We proposed a novel intra-operative diagnostic method, Machine Learning Cascade (MLC)-based Raman histopathology, which uses a coordinate localization system (CLS), hierarchical clustering analysis (HCA), support vector machine (SVM), and similarity analysis (SA). This method enables visualization of PD-L1 expression in glioma cells, CD8 T cells, macrophages, and normal cells in addition to the tumor/normal boundary. The study quantified PD-L1 expression levels using the tumor proportion, combined positive, and cellular composition scores (TPS, CPS, and CCS, respectively) based on Raman data. Furthermore, the association between Raman spectral features and biomolecules was examined biochemically.
The entire process from signal collection to visualization could be completed within 30 min. In an orthotopic glioma mouse model, the MLC-based Raman histopathology demonstrated a high average accuracy (0.990) for identifying different cells and exhibited strong concordance with multiplex immunofluorescence (84.31 %) and traditional pathologists' scoring (R ≥ 0.9). Moreover, the peak intensities at 837 and 874 cm showed a positive linear correlation with PD-L1 expression level.
This study introduced a new and extendable diagnostic method to achieve rapid and accurate visualization of PD-L1 expression in GBM IMB at the tissular level, leading to great potential in GBM intraoperative diagnosis for guiding surgery and post-operative immunotherapy.
联合免疫疗法有望提高反应性胶质母细胞瘤(GBM)患者的生存率。免疫微环境(IME)中的程序性死亡配体 1(PD-L1)表达是免疫治疗最重要的预测生物标志物。由于 PD-L1 的异质性分布,术后组织病理学无法准确捕捉残留肿瘤中的表达,因此术中诊断对于 GBM 治疗策略至关重要。然而,目前评估 PD-L1 表达的方法仍然耗时。
克服 PD-L1 的异质性,实现 GBM IME 中 PD-L1 表达水平的快速、准确和无标记成像。
我们提出了一种新的术中诊断方法,基于机器学习级联(MLC)的拉曼组织病理学,该方法使用坐标定位系统(CLS)、层次聚类分析(HCA)、支持向量机(SVM)和相似性分析(SA)。该方法能够可视化胶质瘤细胞、CD8 T 细胞、巨噬细胞和正常细胞中的 PD-L1 表达,以及肿瘤/正常边界。该研究使用拉曼数据量化 PD-L1 表达水平,采用肿瘤比例、联合阳性和细胞成分评分(TPS、CPS 和 CCS)。此外,还从生物化学角度研究了拉曼光谱特征与生物分子之间的关系。
从信号采集到可视化的整个过程可以在 30 分钟内完成。在原位胶质瘤小鼠模型中,基于 MLC 的拉曼组织病理学对识别不同细胞具有很高的平均准确率(0.990),与多重免疫荧光(84.31%)和传统病理学家评分具有很强的一致性(R≥0.9)。此外,837 和 874 cm 处的峰强度与 PD-L1 表达水平呈正线性相关。
本研究引入了一种新的可扩展诊断方法,可在组织水平上快速准确地可视化 GBM IMB 中的 PD-L1 表达,为指导手术和术后免疫治疗的 GBM 术中诊断提供了巨大潜力。